Ofor

General characteristics. Structure:

Active ingredients: 200 mg of an ofloksatsin, 500 mg of an ornidazol

Excipients: starch corn, povidone (PVPK-30), magnesium stearate, sodium of a kroskarmelloz, silicon dioxide colloid anhydrous, опадрай white 31G58920 (gipromelloza; lactoses monohydrate; titanium dioxide (Е 171); polyethyleneglycol 4000; talc; polyethyleneglycol 400), talc of clarifications, "yellow decline" dye (Е 110), titanium dioxide (Е 171), polyethyleneglycol 6000.

The combined medicine having antimicrobic and anti-protozoan effect.

Pharmacological properties:

Pharmacodynamics. Ofloxacin is the representative of the first generation of ftorkhinolon, has high bactericidal activity. The bactericidal effect is connected with influence on gene DNK-gidrazu and a topomeraza that causes oppression of cell division with development of structural changes. Shows antibacterial activity concerning grams (+) and gram(s) of bacteria: Citrobacter diversus, Citrobacter diversus, Enterobacter aerogenes, E. coli, Streptococcus pyogenes, Klebsiella pneumoniae, Pr. mirabilis, Pseudomonas aeruginosa, ureaplasma, causative agent of gonorrhea, causative agent of clamidiosis, mycoplasma, golden staphylococcus. Renders activity to strains resistant to other antibiotics and to sulfanamide drugs.

Ornidazol belongs in group of derivatives 5 nitroimidazoles (5-NIMZ). Feature of drug is presence in it of the free radical – chlorine atom which gets in the microbic agent by active and passive transport. Getting into a cell the nitroimidazole forms complexes with DNA, causing its degeneration. Also DNA replication processes are as a result broken that causes death of a bacterium.
The nitroimidazole has at the same time cytotoxic effect on a cell and breaks processes of cellular respiration. Is the antimicrobic means of systemic action influencing gram (+) and gram(s) anaerobic a bacterium and protozoa: bacteroids, Fusobacterium spp., Eubacterium spp., clostridiums, peptokokk - Peptococcus, Peptostreptococcus, G. Vaginalis, trichomonads, a dysenteric amoeba, a balantidiya, a lyambliya, a leushmania.

Pharmacokinetics. Ofloxacin is quickly absorbed by a GIT. Bioavailability of an ofloksatsin is equal to 96% after primary use. Meal slightly detains absorption, but does not change its concentration in blood. The T period ½ makes 5-8 hours. 25% of drug are in the connected state with albumine. Ofloxacin not changed with urine for 24-48 hours Eliminirutsya. Since elimination happens kidneys, at HPN its pharmacokinetics significantly changes.

Well gets into breast milk and through an uteroplacental barrier. It is actively distributed in biological environments of an organism, getting into bile, saliva, a prostate, a bronchial secret, ascitic liquid, a bone tissue.

Ornidazol reaches bioavailability after oral administration to 100%. The maximum concentration is observed 3 hours later. The elimination half-life is equal 10-14 hours. Communication with blood proteins is insignificant - to 15%. Well gets into cerebrospinal fluid, etc. biological environments of an organism. It Eliminirutsya with urine to 65% (in an invariable look), with a stake to 25%. 85% of an ornidazol eliminirutsya the first five days from the moment of the first reception.

Indications to use:

- Diseases of an urogenital path with the microbic agents who are giving in to treatment by drug components (including the prostatitis caused by E. coli.);
- infectious diseases of generative organs (gonorrhea, clamidiosis, trichomoniasis);
- infectious diseases of respiratory system;
- infectious diseases of a GIT and bile-excreting system (amebiasis, lambliasis);
- infectious processes of integuments and soft tissues;
- preoperative antibiotikoprofilaktika.

Route of administration and doses:

Ofor is recommended for peroral use. Is accepted inside after the use of food.

Amebiasis: on 1 таб. twice a day 5 days.

Amoebic dysentery: on 1 таб. three times a day 3 days.

Lambliasis: on 1 таб. three times a day 1-2 days.

Trichomoniasis: on 1 таб. twice a day 5 days.

Bacterial vaginosis: 3 таб. in one step. Once.

At other diseases the dose is calculated individually depending on a type of the activator and weight of process.

Features of use:

With care appoint to patients with diseases of the central nervous system, for example with epilepsy, damage of a brain, multiple sclerosis, atherosclerosis of brain vessels.

In case of exceeding of the recommended doses the risk of development of indirect actions increases.

During pregnancy and a lactation Ofor can be used only if the potential advantage justifies potential risk for a fruit. In the investigation of the fact that, authentically, serious adverse reactions for the child are possible the decision has to be made concerning feeding cancellation груддю or drug withdrawals, taking into consideration importance of treatment for mother.

It is necessary to be careful at appointment to children in cases of urgent requirement.

During treatment it is necessary to avoid insolation. For anticipation of development of a crystalluria it is necessary to provide the sufficient drinking mode.

Side effects:

Frequency of occurrence of negative effects increases at non-compliance with sredneterapevtichesky doses.

Changes of a GIT: nausea, vomiting, appetite disturbance, disturbance of a chair, metal or bitter taste in a mouth, swelling of intestines, an abdominal pain, the salivation increased.

Changes of respiratory system: a stethalgia and in a nasal cavity, pharyngitis.

Changes of TsNS: headache, weakness, faints, incoordination, confusion of consciousness, drowsiness, concern, neuropathy, feeling of heat.

Blood changes: decrease in neutrophils, medullary aplasia.

Changes as a vaginitis, an itch of genitalias at women. Allergic manifestations in the form of skin rashes and an itch.

Interaction with other medicines:

Alcohol intake for treatment by Ofor is not recommended.

The anticoagulants applied along with Ofor increase probability of hemorrhages and bleedings.

Antiacid means at the heart of which magnesium, calcium or aluminum, drugs from two - or trivalent cations contains (iron), polyvitamins containing zinc are accepted with an interval two hours between Ofor's use.

Cimetidinum at a concomitant use with Ofor causes increase in an elimination half-life and level of drug in blood, in particular its component – an ofloksatsin.

The ofloxacin which is contained in drug oppresses activity of P450 cytochrome that can raise an elimination half-life for the means which are metabolized this system (cyclosporine, theophylline, warfarin, methylxanthine).

NPVS against the background of Ofor's reception increase probability of emergence of convulsive attacks as result of excitement of TsNS.

Probenetsid and Ofor mutually reduce elimination of each other that causes development of negative effects of drug.

Theophylline against the background of Ofor increases the bioavailability and an elimination half-life that it is capable to provoke overdose manifestations by theophylline.

Ofor at a concomitant use with warfarin changes a blood clotting time and a prothrombin time.

Glucose-lowering drugs against the background of treatment by Ofor change the bioavailability and changes of indicators of glucose of blood are observed, is more often than a hypoglycemia. It is recommended to carry out more careful control of a course of diabetes against the background of treatment by Ofor.

Contraindications:

Individual intolerance of components of drug. Pregnancy. Lactation. A children's age group up to 16 years.

Overdose:

At overdose by drug development of the expressed side effects is characteristic.

As treatment symptomatic therapy is used. At a convulsive syndrome diazepam is applied. The hemodialysis, peritoneal dialysis reduce concentration of drug in blood a little.

Storage conditions:

To store in unavailable to children, the dry place at a temperature not above 25 degrees Celsius

Issue conditions:

According to the recipe

Packaging:

On 10 tablets in the blister, on 1 blister in cardboard packaging.